NGR-hTNF in Combination With an Anthracycline in Platinum-resistant Ovarian Cancer (NGR018)

NCT03804866 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

INDUSTRY

Sponsor class

Conditions

Ovarian Cancer

Interventions

DRUG: NGR-hTNF
DRUG: Pegylated liposomal doxorubicin
DRUG: Doxorubicin

Sponsor

AGC Biologics S.p.A.